Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant or Tamoxifen with Palbociclib in Metastatic Breast Cancer
NCT02913430Phase 1Completed
- Start
- Apr 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in breast cancer comparing Fulvestrant + Palbociclib with Tamoxifen + Palbociclib (2 arms). Primary endpoint: Progression-Free Survival at 3.96 years. Started Apr 2018; status: completed.
02
Drugs
fulvestranttamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02913430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913430.